制剂研究员/Research Investigator, CMC Drug Product(博士)当面告知
百濟神州有限公司
2026-12-15 15:28:34
校招博士27届
岗位详情
地区:
北京
专业要求:
化学生物科学
岗位职责:
Drug Product (DP) Preformulation function is responsible for the physico-chemical characterization of BeOne’s new drug pipeline, developing formulations for animal PK and preclinical toxicological evaluations, assessing developability, and exploring delivery options to lay down a solid foundation for the subsequent drug product development.
In this position you will be a key member of cross functional teams assessing developability of new chemical entities in BeOne’s discovery pipeline. The applicant should have strong knowledge of physicochemical and biopharmaceutical properties that are important for oral drug absorption and other drug delivery approaches. The candidate must collaborate effectively across disciplines to holistically assess developability and address needs and challenges.
Job Descriptions:
Lead physicochemical characterization of BeOne’s new chemical entities and developability assessment:
Design and perform diverse in vitro and ex vivo assays to advise project teams on development potential.
Partner with preclinical development for efficient execution of studies.
Summarize results and draw conclusions in team meetings.
Advocate the pharmaceutics perspective within CMC team settings to ensure that biopharmaceutical and physicochemical considerations are incorporated into formulation and process design/development. Provides pharmaceutics support to development projects and address challenges related to physicochemical aspects of drug molecules and dosage forms.
Support the development of technologies and scientific innovations that improve DP’s capability of delivering small molecule pipeline. Advance scientific expertise within function. Proactively demonstrate leadership by advising and sharing knowledge with peers and management.
Publish and/or present in conferences with manager’s supervision, build scientific connections in pharmaceutical science community.
Qualifications:
PhD degree in pharmaceutical science, chemistry, biology, engineering or related fields.
0-2 years working experience on pharmaceutics, solid-state, formulation, analytical or other related fields of drug development.
Fundamental understanding of physicochemical properties as related to drug delivery and preclinical and clinical formulation design.
Working knowledge of physiological barriers to drug absorption, including various potential transport mechanisms.
Working knowledge of formulation and process development.
Technical expertise on common analytical tools for drug substance, formulation and process characterization (e.g. HPLC, DSC, TGA, PXRD, spectroscopy, drug release). Familiarity with basic statistical tools is a plus.
Good learning agility, strong passion for science, and critical thinking.
Capable of cross-functional teamwork.
Good communication skills and demonstrated ability to clearly summarize results for presentation and report generation. Capable of using English as working language (verbal and writing).
招聘要求:
Drug Product (DP) Preformulation function is responsible for the physico-chemical characterization of BeOne’s new drug pipeline, developing formulations for animal PK and preclinical toxicological evaluations, assessing developability, and exploring delivery options to lay down a solid foundation for the subsequent drug product development.
In this position you will be a key member of cross functional teams assessing developability of new chemical entities in BeOne’s discovery pipeline. The applicant should have strong knowledge of physicochemical and biopharmaceutical properties that are important for oral drug absorption and other drug delivery approaches. The candidate must collaborate effectively across disciplines to holistically assess developability and address needs and challenges.
Job Descriptions:
Lead physicochemical characterization of BeOne’s new chemical entities and developability assessment:
Design and perform diverse in vitro and ex vivo assays to advise project teams on development potential.
Partner with preclinical development for efficient execution of studies.
Summarize results and draw conclusions in team meetings.
Advocate the pharmaceutics perspective within CMC team settings to ensure that biopharmaceutical and physicochemical considerations are incorporated into formulation and process design/development. Provides pharmaceutics support to development projects and address challenges related to physicochemical aspects of drug molecules and dosage forms.
Support the development of technologies and scientific innovations that improve DP’s capability of delivering small molecule pipeline. Advance scientific expertise within function. Proactively demonstrate leadership by advising and sharing knowledge with peers and management.
Publish and/or present in conferences with manager’s supervision, build scientific connections in pharmaceutical science community.
Qualifications:
PhD degree in pharmaceutical science, chemistry, biology, engineering or related fields.
0-2 years working experience on pharmaceutics, solid-state, formulation, analytical or other related fields of drug development.
Fundamental understanding of physicochemical properties as related to drug delivery and preclinical and clinical formulation design.
Working knowledge of physiological barriers to drug absorption, including various potential transport mechanisms.
Working knowledge of formulation and process development.
Technical expertise on common analytical tools for drug substance, formulation and process characterization (e.g. HPLC, DSC, TGA, PXRD, spectroscopy, drug release). Familiarity with basic statistical tools is a plus.
Good learning agility, strong passion for science, and critical thinking.
Capable of cross-functional teamwork.
Good communication skills and demonstrated ability to clearly summarize results for presentation and report generation. Capable of using English as working language (verbal and writing).
公司介绍

百濟神州有限公司
百濟神州有限公司,成立于2018-06-28,位于香港,登记状态:仍注册,注册资本15.4142万美元,公司类型:中外合资
百济神州有限公司是一家商业化阶段的生物技术公司,专注于开发及商业化用于治疗癌症的创新型分子靶向及肿瘤免疫治疗药物。百济神州拥有广泛全面的产品组合。其产品包括六种内部开发、临床阶段的候选药物,其中包括三种后期临床候选药物,zanubrutinib(BTK抑制剂),tislelizumab(PD-1抗体)与pamiparib(PARP抑制剂)。百济神州亦获得五种药物及在研药物的授权许可,包括三种已于中国销售的由新基独家授权的药物ABRAXANE、REVLIMID 及VIDAZA,及两种临床阶段的在研药物,该种药物已获得于中国及亚太地区的其他指定国家开发及商业化的权利。百济神州于2010年于北京成立并在2016年2月在美国纳斯达克全球精选市场上市。截至2018年7月,公司拥有一支超过1300名员工的全球团队,成为一家拥有涵盖研究、临床开发、生产及商业化的全面实力的全球生物技术公司。